Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4

Virology Journal

Volumn 4, Issue , 2007, Pages

  Zekri, Abdel Rahman N ^a   El Din, Hanaa M Alam ^a   Bahnassy, Abeer A ^b   Khaled, Mohsen M ^c   Omar, Ashraf ^d   Fouad, Inas ^d   El Hefnewi, Mahmoud ^e,f   Thakeb, Fouad ^d   El Awady, Mostafa ^e,f  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c MINISTRY OF HEALTH   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

^e NATIONAL RESEARCH CENTRE   (Egypt)

^f NONE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

5' UNTRANSLATED REGION; ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FIBROSIS; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENETIC DISTANCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MUTATION; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREDICTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRAL GENETICS;

HEPATITIS C VIRUS;

5' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; EGYPT; FEMALE; GENETIC HETEROGENEITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 33847379731     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-16     Document Type: Article

References (33)

1. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. HJ Alter LB Seeff, Semin Liver Dis 2000 20 1 17 35 10.1055/s-2000-9505 10895429
2. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. A El-Zayadi P Simmonds H Dabbous L Prescott O Selim A Ahdy, J Viral Hepat 1996 3 5 261 264 8914006
3. Genotypes and response to anti-viral therapy among Saudi patients. I Al-Traif FA Handoo A Al-Jumah M Al-Nasser, Saudi Med J 2004 25 12 1935 1938 15711670
4. Hepatitis C virus resistance to antiviral therapy. JM Pawlotsky, Hepatology 2000 32 5 889 896 10.1053/jhep.2000.19150 11050035
5. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. JM Pawlotsky M Pellerin M Bouvier F Roudot-Thoraval G Germanidis A Bastie F Darthuy J Remire CJ Soussy D Dhumeaux, J Med Virol 1998 54 4 256 264 10.1002/(SICI)1096- 9071(199804)54:4256::AID-JMV43.0.CO;2-3 9557291
6. Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. H Toyoda T Kumada S Nakano I Takeda K Sugiyama T Osada S Kiriyama Y Sone M Kinoshita T Hadama, J Hepatol 1997 26 1 6 13 10.1016/S0168-8278(97)80002-5 9148023
7. Therapy of acute and chronic viral hepatitis. JH Hoofnagle, Adv Intern Med 1994 39 241 275 8140956
8. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. I Vuillermoz E Khattab E Sablon I Ottevaere D Durantel C Vieux C Trepo F Zoulim, J Med Virol 2004 74 1 41 53 10.1002/jmv.20144 15258967
9. The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. E Lebovics J Lantin G Chaurushia BM Dworkin A Casellas WS Rosenthal, Am J Gastroenterol 1995 90 6 951 954 7771428
10. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. L Roffi GC Mels G Antonelli G Bellati F Panizzuti A Piperno M Pozzi D Ravizza G Angeli F Dianzani G Mancia, Hepatology 1995 21 3 645 649 10.1016/0270-9139(95) 90512-X 7875661
11. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. RM Hoffmann T Berg G Teuber O Prummer L Leifeld MC Jung U Spengler S Zeuzem U Hopf GR Pape, Z Gastroenterol 1999 37 8 715 723 10494606
12. Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon. S Nakajima T Kuroki M Shintani O Kurai T Takeda S Nishiguchi S Shiomi S Seki K Kobayashi, Hepatology 1990 12 6 1261 1265 2147916
13. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. P Farci R Strazzera HJ Alter S Farci D Degioannis A Coiana G Peddis F Usai G Serra L Chessa G Diaz A Balestrieri RH Purcell, Proc Natl Acad Sci USA 2002 99 5 3081 3086 11880647 10.1073/pnas.052712599
14. Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of Hepatocellular carcinoma. AR Zekri AA Bahnassy SM Shaarawy OA Mansour MA Maduar HM Khaled O El-Ahmadi, J Med Microbiol 2000 49 89 95 10628830
15. TRUGENE Sequencing Versus INNO-LiPA for Sub-Genotyping of HCV Genotype-4. A-RN Zekri HM Alam El-Din AA Bahnassy AMR El-Shehabi H El-Leethy S Omar HM Khaled, J Med Virology 2005 75 412 420 10.1002/jmv.20293
16. NIH Consensus Development Conference Statement: Management of C 2002: A Preliminary Draft Statement, June 10-12, 2002. National Institutes of Health, Bethesda, Maryland. NIH Consensus Development Program 2002
17. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. QL Choo G Kuo AJ Weiner LR Overby DW Bradley M Houghton, Science 1989 244 4902 359 362 10.1126/science.2523562 2523562
18. Comparative analysis of different PCR techniques for detection of HCV in hepatocellular carcinoma patients. A Zekri A Bahnassy H Khaled O Mansour MA Attia, Cancer J 1995 8 331 335
19. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. D Higgins J Thompson T Gibson JD Thompson DG Higgins TJ Gibson, Nucleic Acids Res 1994 22 4673 4680 7984417 10.1093/nar/22.22.4673
20. BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. TA Hall, Nucl Acids Symp Ser 1999 41 95 98
21. Randomized trial of IFN α2b plus ribavirin for 48 weeks or for 24 weeks versus IFN α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo V Bain J Heathcote S Zeuzem C Trepo J Albrecht, Lancet 1998 352 1426 1432 10.1016/S0140-6736(98)07124-4 9807989
22. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. M Manns J McHutchison S Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht, Lancet 2001 358 958 965 10.1016/S0140-6736(01)06102-5 11583749
23. PegIFN-α2a plus ribavirin for treatment of chronic hepatitis C virus infection. MW Fried ML Shiffman R Reedy C Smith G Marinos FL Goncales Jr D Haussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman J Yu, N Engl J Med 2002 347 975 982 10.1056/NEJMoa020047 12324553
24. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. A Koshy P Marcellin M Martinot JP Madda, Liver 2000 20 4 335 339 10.1034/j.1600-0676.2000.020004335.x 10959813
25. Pegylated interferon-alpha- 2b- ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. M Derbala A Amer A Bener AC Lopez M Omar M El Ghannam, Viral hepatitis 2005 12 4 380 385 10.1111/j.1365-2893.2005. 00604.x
26. Immunomodulators, sFas and Fas-L as potential non-invasive predictors of IFN treatment in patients with HCV genotype-4. AR Zekri H Abdel Haleem El-Din G Esmat A Bahnassy HM Alam El-Din MM Hafez AF Sharaby H Sharaf MS Zakaria, Journal of Viral Hepatitis 2006 (Ahead of pubmed, Jan 3, 2007 article number doi:10.1111/j.1365-2893.2006.00832.x)
27. Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil. AV Alves AP de Azevedo C Perin GZ Ramos AB Brandao AA de Mattos PR de Almeida, Arg Gastroenterol 2003 40 4 227 232
28. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. S Fargion AL Fracanzani M Sampietro V Molteni R Boldorini M Mattioli B Cesana G Lunghi A Piperno C Valsecchi G Fiorelli, Eur J Gastroenterol Hepatol 1997 9 5 497 503 9187884
29. Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon. A Garrido JA Lepe FJ Guerrero S Palomo, Enferm Infecc Microbiol Clin 2000 18 10 512 515 11198002
30. Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients. G Fallows K Kaita G Minuk F Penner G Smart M Dawood B Rosser, Can J Gastroenterol 2000 14 Suppl B 30B 35B 10938502
31. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). S Magrin A Craxi C Fabiano L Marino G Fiorentino O Lo Iacono R Volpes V Di Marco P Almasio A Vaccaro MS Urdea JC Wilber C Bonura F Gianguzza V Capursi S Filiberti L Stuyver L Pagliaro, J Hepatol 1996 25 5 583 590 10.1016/S0168-8278(96)80224-8 8938531
32. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. P Farci A Shimoda A Coiana G Diaz G Peddis JC Melpolder A Strazzera DY Chien SJ Munoz A Balestrieri RH Purcell HJ Alter, Science 2000 288 5464 339 344 10.1126/science.288.5464.339 10764648
33. Molecular biology and clinical implicationof hepatitis C virus. AC Lyra X Fan AM Di Bisceglie, Brazilian Journal of Medical and Biological Research 2004 37 691 695 10.1590/S0100-879X2004000500010